15-SORRENTO-Therapeutics-Logo-FINAL.png
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
May 20, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
March 25, 2021 15:58 ET | Sorrento Therapeutics, Inc.
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusionPreparations are ongoing for initiating Phase 2 placebo-controlled...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
January 26, 2021 19:09 ET | Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration  No infusion-related adverse events noted for any patient treated to date  SAN DIEGO, Jan. 26, 2021 ...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies
October 12, 2020 17:21 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem...
FBI LOGO TM.png
[2020-2026] Acute Respiratory Distress Syndrome Treatment Market Size, Share, Growth, Revenue, Potential, Analysis Report
September 24, 2020 06:03 ET | Fortune Business Insights
Pune, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advancements in stem cell research is a major driving factor for the global acute respiratory distress syndrome treatment market growth. According to the...
NeuroRx Logo.jpg
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
June 01, 2020 16:03 ET | NeuroRx
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100Clinical trial to enroll 144 patients total with expansion to additional sites including the...
logo.png
Multiverse Investment Fund Announces Portfolio Company’s Commencement of Clinical Trials to Treat Acute Respiratory Distress Syndrome (ARDS) Caused by Coronavirus (COVID-19)
April 15, 2020 08:30 ET | Multiverse Investment Fund I, LP
Multiverse Investment Fund Portfolio Company Begins Clinical Trials to Treat Acute Respiratory Distress Syndrome (ARDS) Caused by Coronavirus (COVID-19) ARDS has been identified as the leading cause...